Debut Plus

₹10.3

▲ +0.02 +0.19%

As of 23 Oct 2026 · delayed

NSE Listed

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-28
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-31

Nectar Lifesciences Ltd. (NECLIFE)

Volume: 1,01,721Avg Vol 1W: 2,67,787.8Avg Vol 1M: 1,73,390.552W Range:₹9.3₹22.4
Key Ratios
Checked 4h ago
Market Cap₹200 Cr
Current Price₹10.3
Previous Close₹10.28
High / Low (52w)₹22.4 / ₹9.3
Volume1,01,721
Avg Vol (1W)2,67,787.8
Avg Vol (1M)1,73,390.5
Stock P/E—
Book Value₹29.97
Dividend Yield0%
ROE-9.85%
ROA-39.42%
Revenue (TTM)₹9 Cr
Revenue Growth-0.8%
Profit Margin-24,50,600%
Total Debt₹60 Cr
Shares Outstanding19 Cr
Face Value₹1
EPS (TTM)₹0
P/B0.34
Debt / Equity0.38
50 DMA₹11.11
200 DMA₹11.82
Day change+0.19%
SurveillanceLT-ASM · ASM 1
Price Chart
₹10.3▼ 27.97% · 1Y
₹22₹95.3Cr
2025-10-27
2026-10-23

20-day avg volume: 1.7L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 18% YoY.
  • Net profit is growing year over year.
  • Stock trades below its book value.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹6 Cr₹0 Cr₹0 Cr₹5 Cr₹1 Cr₹0 Cr₹1 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-51 Cr₹-24 Cr
Net Profit₹6 Cr₹8 Cr₹-130 Cr₹-63 Cr₹-176 Cr₹14 Cr₹-68 Cr₹-15 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹2 Cr₹0 Cr₹5 Cr₹1 Cr₹0 Cr₹1 Cr₹9 Cr₹0 Cr
EBITDA₹1 Cr₹0 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-51 Cr₹-52 Cr₹-21 Cr
Net Profit₹-114 Cr₹-130 Cr₹-63 Cr₹-176 Cr₹14 Cr₹-68 Cr₹-293 Cr₹-13 Cr
EPS-5.07—————-13.4—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹2,705 Cr₹2,633 Cr₹2,471 Cr₹2,391 Cr₹2,189 Cr₹2,191 Cr₹2,047 Cr₹622 Cr
Total Liabilities₹1,600 Cr₹1,497 Cr₹1,409 Cr₹1,303 Cr₹1,125 Cr₹1,122 Cr₹1,091 Cr₹39 Cr
Equity₹1,105 Cr₹1,136 Cr₹1,062 Cr₹1,088 Cr₹1,065 Cr₹1,069 Cr₹956 Cr₹582 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹253 Cr₹294 Cr₹25 Cr₹95 Cr₹134 Cr₹225 Cr₹169 Cr₹-349 Cr
Investing₹-26 Cr₹-33 Cr₹-29 Cr₹17 Cr₹52 Cr₹-17 Cr₹-42 Cr₹1,208 Cr
Financing₹-201 Cr₹-252 Cr₹11 Cr₹-119 Cr₹-186 Cr₹-205 Cr₹-128 Cr₹-767 Cr
Free Cash Flow₹253 Cr₹294 Cr₹25 Cr₹95 Cr₹134 Cr₹225 Cr₹169 Cr₹-349 Cr
Shareholding
Promoter 51.84% Institutions 4.4% Public 43.76%
Efficiency & Working Capital
ROCE-8.7%
Interest Coverage0
Dividend Payout—
Debtor Days—
Inventory Days—
Payable Days—
Cash Conversion Cycle—
Working Capital Days—
Shareholding Details

As of 2026-09-30

Promoter51.8%
FII0.5%
DII3.9%
Institutions4.4%
Public43.8%
Promoter Pledge0%
No. of Shareholders72,334
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Jan 2026Jan 2026Mar 2026Jun 2026Sept 2026
Promoters55.8%55.8%44.5%44.5%44.5%44.9%44.9%51.8%51.8%51.8%51.8%51.8%
FIIs16.6%3.2%0.7%1.6%0.8%0.6%0.5%0.6%0.6%0.6%0.5%0.5%
DIIs0%0%0%0.2%0.2%0.1%5.8%3.5%3.5%4%3.7%3.9%
Public27.6%41%54.7%53.7%54.5%54.4%48.7%44%44%43.5%43.9%43.8%
Promoter Pledge100%100%99.6%99.6%99.6%98.8%0%0%0%0%0%0%
No. of Shareholders58,23066,74169,48269,24171,97776,47078,12476,64876,64874,83473,83472,334
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Sanjiv GoyalShareholding of Promoter and Promoter Group24.6%4.78 Cr
Sanjiv (huf) - Karta Sanjiv GoyalShareholding of Promoter and Promoter Group22.5%4.36 Cr
Raman GoyalShareholding of Promoter and Promoter Group4.8%92,38,448
Rajasthan Global Securities Private LimitedPublic Shareholding3.9%75,77,547
Nectar Organics Private LimitedShareholding of Promoter and Promoter Group0%0
Orient Alloys Private LimitedShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Sanjiv GoyalChairman / Executive Director / M D / Promoter2026
Rupinder TewariIndependent Non Exe. Director2026
Kuldip Kumar BhasinIndependent Non Exe. Director2026
Indu Pal KaurIndependent Non Exe. Director2026
Sushil KapoorDirector (Finance) & CFO2026
Gunmala SuriIndependent Non Exe. Director2026
Sanjaymohan Singh RawatCompany Sec. & Compli. Officer2026
Segments — Product
SegmentRevenueShare
Pharmaceuticals Products₹0 Cr—
Segments — Geography
RegionRevenueShare
India₹302 Cr64.2%
Outside India₹169 Cr35.8%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹1351919
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-14Board Meetings—
buyback2026-01-06₹27 max—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20269900150114
20269800140112
2026100102
Insider / Designated-Person Trades

5 recent disclosure(s)

Raman GoyalAcquisition · 80,00,000
Sanjiv GoyalDisposal · 80,00,000
SBICAP Trustee Company LimitedRevoke · 9,94,68,000
SanjivHUFRevoke · 4,36,22,400
Sanjiv GoyalRevoke · 5,58,45,600
Substantial Acquisitions (SAST)

3 disclosure(s)

Buy Back20/01/2026 · —
Market12/12/2025 · 3,62,422
Release Of Pledge30/10/2025 · —
Company Information
Incorporated1995
ChairmanSanjiv Goyal
AuditorDeepak Jindal & Co
Investor Email[email protected]
🌐 www.neclife.com ↗

📍 Village Saidpura, Tehsil Derabassi S A S Nagar, Mohali, Punjab, 140507

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search